Small molecule · Inhibitor of transducin beta-like protein 1 (TBL1XR1) · developed by Iterion Therapeutics
Phase 1/2Most advanced trial
1Registered trials
What is Tegavivint?
Tegavivint is a small molecule inhibitor of the Wnt/beta-catenin pathway. It binds transducin beta-like protein 1 (TBL1), disrupting its binding to beta-catenin, which promotes beta-catenin degradation and reduces TCF4-driven transcription. It is being studied in hepatocellular carcinoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
BC-2059
Drug type
Small molecule
Targets
transducin beta-like protein 1 (TBL1XR1), beta-catenin (CTNNB1) (binding partner it blocks)
Mechanism
Inhibitor of transducin beta-like protein 1 (TBL1XR1)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.